Your browser is no longer supported. Please, upgrade your browser.
Settings
REPH Recro Pharma, Inc. daily Stock Chart
REPH [NASD]
Recro Pharma, Inc.
Index- P/E- EPS (ttm)-2.43 Insider Own27.40% Shs Outstand18.26M Perf Week-52.65%
Market Cap101.34M Forward P/E- EPS next Y-1.56 Insider Trans-16.48% Shs Float18.09M Perf Month-51.74%
Income-46.50M PEG- EPS next Q-1.03 Inst Own72.60% Short Float2.57% Perf Quarter-37.71%
Sales72.60M P/S1.40 EPS this Y21.50% Inst Trans2.61% Short Ratio1.18 Perf Half Y-40.83%
Book/sh1.28 P/B4.34 EPS next Y53.30% ROA-31.00% Target Price18.25 Perf Year-32.73%
Cash/sh2.81 P/C1.98 EPS next 5Y- ROE-136.10% 52W Range5.00 - 13.05 Perf YTD-40.00%
Dividend- P/FCF- EPS past 5Y-43.60% ROI-37.10% 52W High-57.47% Beta-0.82
Dividend %- Quick Ratio1.60 Sales past 5Y- Gross Margin47.40% 52W Low11.00% ATR1.04
Employees255 Current Ratio1.80 Sales Q/Q4.30% Oper. Margin-63.30% RSI (14)22.42 Volatility11.94% 6.22%
OptionableYes Debt/Eq0.00 EPS Q/Q-52.70% Profit Margin-75.00% Rel Volume3.88 Prev Close5.63
ShortableYes LT Debt/Eq2.20 EarningsMay 09 BMO Payout- Avg Volume392.08K Price5.55
Recom1.60 SMA20-50.30% SMA50-50.08% SMA200-40.59% Volume1,522,786 Change-1.42%
Feb-14-18Initiated Oppenheimer Outperform $19
Dec-19-16Initiated Piper Jaffray Overweight $12
Nov-14-16Initiated Aegis Capital Buy $21
Oct-03-16Resumed Brean Capital Buy
Sep-16-16Initiated ROTH Capital Buy
Nov-24-15Resumed H.C. Wainwright Buy $14
Sep-02-15Initiated H.C. Wainwright Buy $19
Jun-18-15Reiterated Brean Capital Buy $26 → $28
Apr-14-15Reiterated MLV & Co Buy $12 → $22
Jun-12-14Initiated Aegis Capital Buy $40
Mar-20-14Initiated Brean Capital Buy $26
May-25-18 03:50PM  SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Recro Pharma, Inc. Business Wire
12:55PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Recro Pharma, Inc. - REPH PR Newswire
08:10AM  Todays Research Reports on Stocks to Watch: Recro Pharma and Stellar Biotechnologies ACCESSWIRE
May-24-18 10:11AM  FDA Declines Recro's IV Meloxicam Application Benzinga -54.67%
09:54AM  Recro Pharma shares plummet after FDA rejects non-opioid pain shot Reuters
08:45AM  Recro Pharma's stock loses more than half its value after receiving CRL from FDA MarketWatch
07:07AM  FDA declines to approve Recro Pharma's non-opioid pain shot Reuters
07:00AM  Recro Pharma Receives Complete Response Letter from the FDA GlobeNewswire
May-10-18 01:56PM  Edited Transcript of REPH earnings conference call or presentation 9-May-18 12:00pm GMT Thomson Reuters StreetEvents
May-09-18 07:20AM  Recro Pharma: 1Q Earnings Snapshot Associated Press
07:00AM  Recro Pharma Reports First Quarter 2018 Financial Results GlobeNewswire
May-07-18 07:00AM  Recro Pharma Announces Receipt of Issue Notifications for Three New Patents for IV Meloxicam GlobeNewswire
May-02-18 04:05PM  Recro Pharma Announces Commercial Team Additions GlobeNewswire
07:00AM  Recro Pharma to Report First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9, 2018 GlobeNewswire
Apr-30-18 07:00AM  Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting GlobeNewswire
Apr-16-18 07:00AM  Recro Pharma to Present IV Meloxicam Data at the 43rd Annual Regional Anesthesiology and Acute Pain Medicine Meeting GlobeNewswire
Mar-29-18 04:05PM  Recro Pharma Announces Commercial Team Additions GlobeNewswire
07:00AM  Wired News Recro Pharma Publishes Data from Phase-III Trial for IV Meloxicam ACCESSWIRE
Mar-27-18 07:00AM  Recro Pharma Announces Publication of Phase III IV Meloxicam Bunionectomy Data in the Clinical Journal of Pain GlobeNewswire
Mar-21-18 07:00AM  Recro Pharma to Present at the 17th Annual Needham Healthcare Conference GlobeNewswire +5.89%
Mar-06-18 07:00AM  Recro Pharma to Present at Upcoming Investor Conferences GlobeNewswire
Mar-05-18 07:00AM  Recro Pharma Announces an Educational Symposium on Challenges in Acute Pain Management and Advances in Evidence-Based Management Approaches at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting GlobeNewswire
Mar-02-18 06:48PM  Recro Pharma Inc (REPH) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com +8.01%
04:05PM  Recro Pharma Announces Commercial Team Additions GlobeNewswire
Feb-27-18 07:00AM  Recro Pharma Reports Year End 2017 Financial Results GlobeNewswire
Feb-21-18 07:00AM  Recro Pharma to Host Analyst and Investor Day on February 28, 2018 GlobeNewswire
Feb-20-18 07:00AM  Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam Bunionectomy Data in the Journal of Pain Research GlobeNewswire
Feb-02-18 07:00AM  Recro Pharma Announces Key Sales Team Additions GlobeNewswire
Jan-17-18 08:45AM  Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam Data in the Journal of Clinical Pharmacology GlobeNewswire
Jan-03-18 11:16AM  UPDATE Recro Pharma Announces Key Executive Promotions to the Financial Team GlobeNewswire
07:00AM  Recro Pharma Announces Key Executive Promotions to the Financial Team GlobeNewswire
Dec-29-17 07:00AM  Recro Pharma Reports Inducement Grants for New Staff GlobeNewswire
Dec-26-17 12:01PM  ETFs with exposure to Recro Pharma, Inc. : December 26, 2017 Capital Cube
Dec-25-17 09:27AM  Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Nov-20-17 07:00AM  Recro Pharma Secures $100 Million Credit Facility GlobeNewswire
Nov-09-17 09:37AM  Recro Pharma reports 3Q loss Associated Press
07:00AM  Recro Pharma Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-08-17 07:00AM  Recro Pharma to Present at Upcoming Investor Conferences GlobeNewswire
Oct-31-17 07:00AM  Recro Pharma Reports Inducement Grants for New Staff GlobeNewswire
Oct-10-17 07:00AM  Recro Pharma Presents Phase III IV Meloxicam Clinical Efficacy Data in Patients Following Abdominoplasty at the 2017 American Society of Plastic Surgeons Annual Meeting GlobeNewswire
Oct-09-17 11:59AM  ETFs with exposure to Recro Pharma, Inc. : October 9, 2017 Capital Cube
Oct-06-17 09:12AM  Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Capital Cube
Oct-05-17 05:00PM  Recro Pharma to Participate in Upcoming Investor Conferences GlobeNewswire
07:00AM  Recro Pharma Announces PDUFA Date for IV Meloxicam 30mg GlobeNewswire
Sep-29-17 07:00AM  Recro Pharma Reports Inducement Grants for New Staff GlobeNewswire
Sep-28-17 07:00AM  Recro Pharma Announces FDA Acceptance for Review of New Drug Application for IV Meloxicam 30mg GlobeNewswire
Sep-05-17 07:00AM  Recro Pharma Presents Phase III IV Meloxicam Clinical Safety and Opioid Use Data at PAINWeek® 2017 GlobeNewswire
Aug-25-17 10:45AM  Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars Zacks
Aug-24-17 10:57AM  Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View Zacks
Aug-21-17 07:00AM  Recro Pharma Appoints Jyrki Mattila as Executive Vice President of Business Development GlobeNewswire
Aug-10-17 11:51PM  Recro Pharma reports 2Q loss Associated Press
03:00PM  Recro Pharma Reports Inducement Grants for New Staff GlobeNewswire
07:00AM  Recro Pharma Reports Second Quarter 2017 Financial Results GlobeNewswire
Jul-31-17 07:00AM  Recro Pharma Submits New Drug Application for IV Meloxicam 30mg GlobeNewswire
Jul-21-17 07:00AM  Recro Pharma Reports Inducement Grants for New Staff GlobeNewswire
Jul-10-17 07:00AM  Recro Pharma Reports Inducement Grants for New Staff GlobeNewswire
Jul-05-17 08:00AM  Recro Pharma Acquires Novel Neuromuscular Blocking Agents GlobeNewswire
Jun-26-17 07:00AM  Recro Pharma Added to the Russell 3000® Index GlobeNewswire
Jun-16-17 04:14PM  ETFs with exposure to Recro Pharma, Inc. : June 16, 2017 Capital Cube
07:00AM  Recro Pharma to Participate in Hospital Drug Launch Panel at the JMP Life Sciences Conference GlobeNewswire
Jun-15-17 07:00AM  Recro Pharma Reports Inducement Grants for New Staff GlobeNewswire
Jun-14-17 09:29AM  Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
Jun-06-17 07:00AM  Recro Pharma Appoints Ryan D. Lake as Senior Vice President of Finance and Chief Accounting Officer GlobeNewswire
Jun-02-17 07:00AM  Recro Pharma to Participate in Upcoming Investor Conferences GlobeNewswire
May-18-17 08:00AM  Recro Pharma Presents Phase III Bunionectomy Clinical Data for IV Meloxicam at the American Pain Society 36th Annual Scientific Meeting GlobeNewswire
May-15-17 07:00AM  Recro Pharma to Present Phase III Bunionectomy Clinical Data for IV Meloxicam at the American Pain Society 36th Annual Scientific Meeting GlobeNewswire +7.21%
May-11-17 09:04AM  Recro Pharma reports 1Q loss Associated Press
07:00AM  Recro Pharma Reports First Quarter 2017 Financial Results GlobeNewswire
May-09-17 07:00AM  Recro Pharma Announces Successful Top-Line Results from Phase III Safety Study of IV Meloxicam GlobeNewswire
Apr-07-17 05:22PM  ETFs with exposure to Recro Pharma, Inc. : April 7, 2017 Capital Cube
Mar-29-17 07:00AM  Recro Pharma to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-17-17 09:23AM  Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Capital Cube
09:23AM  Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
Mar-16-17 10:16AM  Recro Pharma, Inc. :REPH-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017 Capital Cube
10:16AM  Recro Pharma, Inc. :REPH-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
07:00AM  Recro Pharma to Present at the Oppenheimer 27th Annual Healthcare Conference GlobeNewswire
Mar-15-17 01:04PM  RECRO PHARMA, INC. Financials
Mar-09-17 03:04PM  RECRO PHARMA, INC. Files SEC form 10-K, Annual Report
Mar-07-17 06:04AM  RECRO PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Stateme
Mar-06-17 04:05PM  Recro Pharma Reports Year End 2016 Financial Results GlobeNewswire
02:21PM  RECRO PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements
07:00AM  Recro Pharma Appoints Bryan Reasons to Its Board of Directors GlobeNewswire
Mar-02-17 07:00AM  Recro Pharma to Present at Upcoming Investor Conferences GlobeNewswire
Feb-27-17 09:18AM  RECRO PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +7.25%
07:00AM  Recro Pharma Completes Enrollment in Phase III Safety Study of IV Meloxicam GlobeNewswire
Jan-18-17 02:50PM  Exclusive: Recro Pharma CEO Talks Meloxicam, Alleviating Investor Concerns Benzinga
Jan-06-17 04:32PM  RECRO PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Dec-19-16 06:48AM  Coverage initiated on Recro Pharma by Piper Jaffray
Dec-16-16 04:03PM  RECRO PHARMA, INC. Files SEC form 8-K, Other Events
09:27AM  Recro Pharma Announces Closing of $40 Million Public Offering of Common Stock GlobeNewswire
Dec-15-16 08:23PM  Is ModusLink Global Solutions, Inc. (MLNK) A Good Stock to Buy? at Insider Monkey -5.37%
06:28PM  How Intrepid Potash, Inc. (IPI) Stacks Up Against Its Peers at Insider Monkey
02:12PM  5 Stocks Insiders Love Right Now
Dec-13-16 01:00PM  Here's how a Malvern pharma firm plans to spend its $36M in stock proceeds at bizjournals.com +9.32%
09:10AM  Recro Pharma Announces Pricing of Public Offering of Common Stock GlobeNewswire
Dec-12-16 02:50PM  ETFs with exposure to Recro Pharma, Inc. : December 12, 2016 -6.75%
Dec-08-16 11:50AM  Recro Pharma Secondary Offering (UPDATE) -5.44%
09:02AM  Recro Pharma Announces Proposed Public Offering of Common Stock GlobeNewswire
06:31AM  RECRO PHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Dec-01-16 11:25AM  Recro Pharma Files for Secondary Offering Following Big Late-Stage Win -19.00%
Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. It also develops Dex-IN, an intranasal formulation of dexmedetomidine for treating post-operative pain and peri-procedural pain; two novel neuromuscular blocking agents and a related proprietary chemical reversal agent; and Fadolmidine for use in as human therapeutic. The company also provides contract development and manufacturing services. Recro Pharma, Inc. has a license agreement with Orion Corporation for the development and commercialization of Dexmedetomidine. It focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Broadfin Healthcare Master Fun10% OwnerMay 24Sale5.81188,0001,093,1822,048,025May 24 05:02 PM
Broadfin Healthcare Master Fun10% OwnerMar 13Sale10.07200,0002,014,0002,236,025Mar 15 04:11 PM
Berelowitz MichaelDirectorMar 09Option Exercise2.477,50018,5257,500Mar 13 04:15 PM
Berelowitz MichaelDirectorMar 09Sale10.457,50078,3470Mar 13 04:15 PM
SCP Vitalife Partners (Israel)10% OwnerJan 04Sale8.841,57913,956726,055Jan 08 04:21 PM
SCP Vitalife Partners II LP10% OwnerJan 04Sale8.844,73241,8222,172,900Jan 08 04:20 PM
SCP Vitalife Partners (Israel)10% OwnerJan 03Sale8.736,63557,943727,634Jan 04 07:45 PM
SCP Vitalife Partners II LP10% OwnerJan 03Sale8.7319,863173,4642,177,632Jan 04 07:45 PM
SCP Vitalife Partners (Israel)10% OwnerJan 02Sale9.046,32957,195734,269Jan 04 07:45 PM
SCP Vitalife Partners II LP10% OwnerJan 02Sale9.0418,947171,2242,197,495Jan 04 07:45 PM
SCP Vitalife Partners (Israel)10% OwnerDec 29Sale9.194,11037,791740,598Jan 02 04:07 PM
SCP Vitalife Partners II LP10% OwnerDec 29Sale9.1912,305113,1422,216,442Jan 02 04:06 PM
SCP Vitalife Partners (Israel)10% OwnerDec 28Sale9.441,98018,690744,708Jan 02 04:07 PM
SCP Vitalife Partners II LP10% OwnerDec 28Sale9.445,92655,9382,228,747Jan 02 04:06 PM
SCP Vitalife Partners (Israel)10% OwnerDec 27Sale9.542,80326,737746,688Dec 28 04:21 PM
SCP Vitalife Partners II LP10% OwnerDec 27Sale9.548,39180,0402,234,673Dec 28 04:21 PM
SCP Vitalife Partners (Israel)10% OwnerDec 26Sale9.591,60215,364749,491Dec 28 04:21 PM
SCP Vitalife Partners II LP10% OwnerDec 26Sale9.594,79846,0162,243,064Dec 28 04:21 PM
Broadfin Healthcare Master Fun10% OwnerDec 21Sale9.8151,000500,2402,436,025Dec 22 04:05 PM
Broadfin Healthcare Master Fun10% OwnerDec 20Sale10.0025,000250,0002,487,025Dec 22 04:05 PM
Broadfin Healthcare Master Fun10% OwnerDec 13Sale9.8218,137178,1392,512,025Dec 14 04:12 PM
Broadfin Healthcare Master Fun10% OwnerDec 12Sale9.8775,100740,9892,530,162Dec 14 04:12 PM
Broadfin Healthcare Master Fun10% OwnerDec 05Sale10.00100,0001,000,0002,605,262Dec 07 04:14 PM
Broadfin Healthcare Master Fun10% OwnerNov 30Sale9.56168,4031,610,2172,705,262Nov 30 05:38 PM
Broadfin Healthcare Master Fun10% OwnerNov 29Sale9.676,66464,4322,873,665Nov 30 05:38 PM
Broadfin Healthcare Master Fun10% OwnerNov 28Sale9.6447,549458,4132,880,329Nov 30 05:38 PM
Broadfin Healthcare Master Fun10% OwnerNov 24Sale9.3718,114169,7352,927,878Nov 24 01:32 PM
Broadfin Healthcare Master Fun10% OwnerNov 22Sale9.3751,654483,9672,945,992Nov 24 01:32 PM
Broadfin Healthcare Master Fun10% OwnerNov 21Sale9.50102,440972,8632,997,646Nov 24 01:32 PM
Flynn James EPossible Member of 10% GroupJun 14Sale6.2568,000425,0001,176,685Jun 14 08:13 PM
Flynn James EPossible Member of 10% GroupJun 13Sale6.5932,447213,8261,244,685Jun 14 08:13 PM
Flynn James EPossible Member of 10% GroupJun 12Sale6.7410,00067,4001,277,132Jun 14 08:13 PM
Flynn James EPossible Member of 10% GroupJun 08Sale6.9917,245120,5431,287,132Jun 09 04:07 PM
Flynn James EPossible Member of 10% GroupJun 07Sale7.0945,623323,4671,304,377Jun 09 04:07 PM